



## 3.4.10 Hospital Pharmacy

1 Introduction

2 Executive summary

3 Research areas and groups

4 Associated clinicians



Publications: 7 | Q1: 5

### COMPOSITION

#### Alicia Herrero Ambrosio.

Jefa de Servicio de Farmacia Hospitalaria. Hospital Universitario La Paz/ Profesora Asociada. Universidad Complutense de Madrid

- **Susana Andrés Morera.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Cristina Bilbao Gómez-Martino.** *Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP*
- **Cristina Cárdenas Serralde.** *Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP*
- **María Gema Casado Abad.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*

- **María del Río Durango.** *Farmacéutico Especialista en Farmacia Hospitalaria. FIBHULP*
- **Macarena García-Trevijano Cabetas.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Luis González del Valle.** *Jefe de Sección de Farmacia Hospitalaria. Hospital Universitario La Paz*
- **María Ángeles González Fernández.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Catalina Lara Cátedra.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Marta Moro Agud.** *Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Tamara Pérez Robles.** *Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP*
- **Elena María Rodríguez Martín.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **José Antonio Romero Garrido.** *Farmacéutico Adjunto. Hospital Universitario La Paz*
- **Rosario Fátima Ros Catellar.** *Farmacéutico Especialista en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Margarita Ruano Encinar.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Luis Sánchez-Rubio Fernández.** *Facultativo Especialista de Área en Farmacia Hospitalaria. FIBHULP*
- **Carmen Sobrino Jiménez.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **María Luisa Testillano Tarrero.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*
- **Elena Villamañán Bueno.** *Facultativo Especialista de Área en Farmacia Hospitalaria. Hospital Universitario La Paz*

### STRATEGIC OBJETIVES

- The research lines of Hospital Pharmacy are oriented towards the study, research and innovation of medicines and technologies related to the pharmacotherapeutic process to optimize care practice.

### RESEARCH LINES

1. Evaluation of Drugs - Real World Outcomes, especially those associated with high economic impact or with limited clinical evidence. In this regard, our target is to investigate on the following fields:
  - Coagulopathies
  - Oncology
  - Biologic therapies
  - Infectious diseases
  - Rare diseases
  - Gene therapy
  - Molecular biology of the innate immune system
2. Research on early detection and prevention strategies for medication errors in both critically ill patients and patients with complex chronic diseases.
3. Analysis of the impact on medication adherence and health outcomes of innovation in new technologies applied to the medication use process:
  - Telepharmacy programs, with or without home delivery of medications. Evaluation of their impact on medication adherence and health outcomes in different pathologies such as migraine, multiple sclerosis, prostate cancer, and asthma.
  - Research on the effect of predictive analytics and big data on clinical decision-making and the optimization of pharmaceutical outcomes.
  - Identification of signaling pathways that connect alpha7 nicotinic receptors and negative regulators of TLR-mediated inflammation in human macrophages.
4. Development of new medicines:
  - Advanced therapies

## 1 Introduction

## 2 Executive summary

## 3 Research areas and groups

## 4 Associated clinicians

### RESEARCH ACTIVITY



#### Publications

- Arteaga M, López-Duque L, Laorden D, Torrado I, Romero-Ribate D, Villamañán E, Quirce S, Álvarez-Sala R, Domínguez-Ortega J. Inhaled corticosteroid reduction effects on asthma outcomes after three years of benralizumab treatment in severe asthma patients. Arch Bronconeumol. 2026; 62(2): 130-2. Letter. IF: 8.7; D1
- Mendoza-Palomar N, Nebot SS, Roig-Soria L, García LA, Anto CI, Ascaso MTG, Pérez DD, Lozano CG, Núñez CJ, López EMR, Gómez MLN, Gallego BC, Vallejo BA, Amador JTR, Manzanares A, Montero BJ, Julian AN, Soler-

Palacin P. Real-life use of isavuconazole in Spanish children and adolescents. J Antimicrob Chemoth. 2026; 81(1): dkaf394. Article. IF: 4.1; Q1

- Rosas-Alonso R, Salas NR, Wert PP, Hoyo A, Martín-López S, Martínez-Pérez D, Ruiz-Gutiérrez I, Jiménez-Bou D, Peña J, Arias P, Custodio A, Losantos-García I, Borobia AM, Feliu J, Ghanem I. DPYD-guided fluoropyrimidine dose adjustment in colorectal cancer DPYD carriers: start slower to finish stronger. Front Pharmacol. 2025; 16: 1645188. Article. IF: 5.4; Q1
- Villamañán E, Laorden D, Ibáñez ME, De las

Vecillas L, Carpio C, Alfonso C, Domínguez-Ortega J, Romero D, Quirce S, Álvarez-Sala R. Adherence to intranasal corticosteroids in patients with severe asthma and nasal polyposis: pharmacological and clinical factors involved. J Clin Med. 2025; 14(14): 5070. Article. IF: 3.3; Q1

- Ramos JR, Perrin RS, Martín MAG, Clemente YC, Díez MA, Pinto AD, Díaz AS, Almela AFD, Serrano PS, Grande ASL, Blanco CC. Adverse drug events associated with emergency departments visits. Emergencias. 2025; 37(3): 196-202. Article. IF: 5.5; Q1
- Galán-Gómez V, González-Martínez B, Alonso-Saladrigues A, Rives S, Herrero B, Kwon M, Sánchez-Pina J, Minguillón J, Martínez-Romera I, Aguilar IM, Mestre-Durán C, Casado G, Sánchez-Martín M, Echecopar C, González-Pérez C, León-Triana O, Aguirre-Portolés C, Molinos-Quintana A, Barba P, Balsalobre P, Pérez-Martínez A. Siltuximab for the treatment of early complications after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia in children, adolescents, and young adults. Exp Hematol Oncol. 2025; 14(1): 49. Article. IF: 17.5; D1
- Sagrado MAR, Criado JA, Pena AEA, Escudero-Vilaplana V, Ollas CF, Fernández MH, Nieto CM, Salvador ARR, Fenollera PS, Castillo MJV. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer: real-world experience at hospitals in Spain. Target Oncol. 2025; 20(2): 319-27. Article. IF: 5.1; Q1
- Castillo MA, Correa-Borit J, Laorden D, Adrianzen F, Villamañán E, Romero D, Quirce S, Domínguez-Ortega J. Eosinophil and cationic protein levels in patients treated with dupilumab: a real-life study. Open Respir Arch. 2025; 7(3): 100444. Article. Not Indexed
- de Andrés Morera S, Chajma Izquierdo S, Arancon Pardo A, Villamañán Bueno E. Implementation of a healthcare network for

the pharmacological treatment adjustment in patients with dysphagia in the hospital and primary care settings. Rev Esp Geriatr Gerontol. 2025; 60(3): 101616. Article. Not Indexed

#### Patents and trademarks

- Villamañán Bueno E, Gómez L, Carpio C, Álvarez-Sala R, Herrero A, authors; FIBHULP, assignees. Brand name: ExpertEPID. 019153209. 2025 July 13.



- "Muñoz M, Villamañán E, Álvarez A, Herrero A, Álvarez-Sala R, Quirce S, González de Olano D, Sánchez Cuellar S, Antolín Américo D, Domínguez Ortega J, Carpio C, Prados MC, authors, FIBHULP, UAM, FIBioHRC, assignees; Brand Name: Checklist. 019168760. 2025 August 02.



- "Villamañán E, Ros Muñoz S, Carpio C, Gómez L, Prados MC, Rodríguez JL, Álvarez-Sala R, Herrero A, Sobrino C, González García L, Caumel Morales L, authors; FIBHULP, UAM, UNED, IN2AI, Patrimonio Nacional, assignees. Brand name: FarmaTOX. 019153050. 2025 July 13.

